About tafasitamab cxix
CD19-directed monoclonal antibody
Used for
- With lenalidomide for adults with relapsed or refractory diffuse large B-cell lymphoma who are not eligible for autologous stem-cell transplant.
- Alone for adults with relapsed or refractory diffuse large B-cell lymphoma after at least two prior treatments.
Usual adult dose
12 mg/kg by intravenous infusion: weekly initially, then every two weeks; schedule and duration depend on treatment combination and response.
Common side effects
- Infusion-related reactions
- Infections
- Low blood-cell counts
- Fatigue and diarrhea
Important warnings
- Serious infections can occur; monitor for infection.
- Infusion reactions may be severe; treatment requires monitoring.
- Low blood-cell counts may require monitoring and treatment adjustments.
- Can cause fetal harm; effective contraception is required during treatment and for three months afterward.
Pregnancy
May cause fetal harm based on its mechanism. Avoid pregnancy during treatment and for three months after the last dose.
Breastfeeding
Avoid breastfeeding during treatment and for at least three months after the last dose.
Interactions
- Lenalidomide is commonly given with tafasitamab for the approved combination treatment.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.